Stocks rose on Monday after a strong gain in retail spending suggested that consumers could be getting more confident about the economy. Bank stocks rose broadly after Citigroup delivered a strong earnings report.
No, it's not easy, but if Grace Groner -- a secretary for 43 years -- could pull off the even more astonishing feat of amassing a $7 million fortune, then it is within the realm of possibility. In fact, Groner's strategy is about the only one with a shot at success. Read on to find out what she did.
Wall Street's consensus sees the S&P 500 tacking on an 11% gain over the next 12 months -- with lots of ups and downs along the way. That has us inclined to play defense, with an eye toward bargain stocks paying generous, sustainable dividends. Here are our top 11 picks for 2011.
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our rundown of the biggest health care stories.
Abbott Laboratories is recalling roughly 359 million blood-sugar test strips for diabetics after the strips turned out to yield falsely low readings.
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a U.S. Department of Justice claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements. This is the fourth such settlement this month alone.
Arena Pharmaceuticals announced, as expected, the U.S. Food and Drug Administration did not approve its weight loss drug Lorcaserin for patients who are obese and overweight because the potential risks outweigh the minimal efficacy.
At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off.
Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.
Abbott has recalled 5 million containers of its top-selling powdered baby formula, Similac, after finding beetles at one of its factories. But parents shouldn't panic, the company says. The chances that any beetlejuice actually made it into the formula is slim, and doctors say babies wouldn't be harmed even if it did.
Giant U.S. pharmaceutical group Abbott Laboratories is cutting 3,000 jobs, or about 3% of its workforce, following its purchase of Belgian-based Solvay's drugs business.
It's a busy day at the FDA today as panels meet to discuss two new drugs -- one to help weight loss and the other to combat drug addiction -- and decide whether to approve AstraZeneca's new blood thinner medication.
Its development of novel treatments for hepatitis C is leading Achillion to seek partnerships with major drugmakers. Many analysts see great potential for its drugs and expect it to strike one or more deals soon.
Abbott Laboratories and Neurocrine Biosciences have entered into a collaboration agreement to develop and commercialize a potential gynecological treatment, elagolix. Elagolix, a potential oral drug, which has completed Phase IIb trials, is being developed for the treatment of endometriosis and uterine fibroids.
Alzheimer's has been a tough area for medical research, resulting in little help to date for the millions of sufferers. But a new database of patient information from failed trials, built by competing drugmakers, may yield clues to a treatment breakthrough.